Ad is loading...
BTAI
Price
$0.57
Change
+$0.05 (+9.62%)
Updated
Nov 15 closing price
109 days until earnings call
INO
Price
$4.26
Change
-$0.51 (-10.69%)
Updated
Nov 15 closing price
Ad is loading...

BTAI vs INO

Header iconBTAI vs INO Comparison
Open Charts BTAI vs INOBanner chart's image
BioXcel Therapeutics
Price$0.57
Change+$0.05 (+9.62%)
Volume$448.31K
CapitalizationN/A
Inovio Pharmaceuticals
Price$4.26
Change-$0.51 (-10.69%)
Volume$670.93K
CapitalizationN/A
BTAI vs INO Comparison Chart
Loading...
BTAI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
INO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
BTAI vs. INO commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BTAI is a Sell and INO is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (BTAI: $0.57 vs. INO: $4.26)
Brand notoriety: BTAI: Not notable vs. INO: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BTAI: 84% vs. INO: 202%
Market capitalization -- BTAI: $23.15M vs. INO: $110.74M
BTAI [@Biotechnology] is valued at $23.15M. INO’s [@Biotechnology] market capitalization is $110.74M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BTAI’s FA Score shows that 0 FA rating(s) are green whileINO’s FA Score has 0 green FA rating(s).

  • BTAI’s FA Score: 0 green, 5 red.
  • INO’s FA Score: 0 green, 5 red.
According to our system of comparison, INO is a better buy in the long-term than BTAI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BTAI’s TA Score shows that 5 TA indicator(s) are bullish while INO’s TA Score has 4 bullish TA indicator(s).

  • BTAI’s TA Score: 5 bullish, 5 bearish.
  • INO’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both BTAI and INO are a good buy in the short-term.

Price Growth

BTAI (@Biotechnology) experienced а -16.43% price change this week, while INO (@Biotechnology) price change was -23.01% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

BTAI is expected to report earnings on Mar 06, 2025.

INO is expected to report earnings on May 08, 2024.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INO($111M) has a higher market cap than BTAI($23.2M). INO YTD gains are higher at: -30.310 vs. BTAI (-80.736). BTAI has higher annual earnings (EBITDA): -93.53M vs. INO (-118.07M). INO has more cash in the bank: 110M vs. BTAI (56.3M). INO has less debt than BTAI: INO (13M) vs BTAI (103M). BTAI has higher revenues than INO: BTAI (2.4M) vs INO (592K).
BTAIINOBTAI / INO
Capitalization23.2M111M21%
EBITDA-93.53M-118.07M79%
Gain YTD-80.736-30.310266%
P/E RatioN/AN/A-
Revenue2.4M592K406%
Total Cash56.3M110M51%
Total Debt103M13M792%
FUNDAMENTALS RATINGS
BTAI vs INO: Fundamental Ratings
BTAI
INO
OUTLOOK RATING
1..100
284
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
54
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
8993
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INO's Valuation (54) in the Medical Specialties industry is in the same range as BTAI (82) in the Biotechnology industry. This means that INO’s stock grew similarly to BTAI’s over the last 12 months.

INO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BTAI (100) in the Biotechnology industry. This means that INO’s stock grew similarly to BTAI’s over the last 12 months.

INO's SMR Rating (97) in the Medical Specialties industry is in the same range as BTAI (100) in the Biotechnology industry. This means that INO’s stock grew similarly to BTAI’s over the last 12 months.

BTAI's Price Growth Rating (89) in the Biotechnology industry is in the same range as INO (93) in the Medical Specialties industry. This means that BTAI’s stock grew similarly to INO’s over the last 12 months.

BTAI's P/E Growth Rating (100) in the Biotechnology industry is in the same range as INO (100) in the Medical Specialties industry. This means that BTAI’s stock grew similarly to INO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BTAIINO
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 12 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
89%
Aroon
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
84%
View a ticker or compare two or three
Ad is loading...
BTAI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
INO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CQP53.000.84
+1.61%
Cheniere Energy Partners LP
BCTX0.60N/A
N/A
BriaCell Therapeutics Corp
ESOA13.85-0.22
-1.56%
Energy Services of America Corp
RPAY7.85-0.14
-1.75%
Repay Holdings Corp
DXC20.81-0.87
-4.01%
DXC Technology Company

BTAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, BTAI has been loosely correlated with ORMP. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BTAI jumps, then ORMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BTAI
1D Price
Change %
BTAI100%
+9.20%
ORMP - BTAI
44%
Loosely correlated
-4.50%
AXON - BTAI
42%
Loosely correlated
-0.86%
INO - BTAI
39%
Loosely correlated
-10.59%
IGMS - BTAI
38%
Loosely correlated
-6.24%
ARRY - BTAI
37%
Loosely correlated
-10.22%
More

INO and

Correlation & Price change

A.I.dvisor indicates that over the last year, INO has been loosely correlated with AXON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INO
1D Price
Change %
INO100%
-10.59%
AXON - INO
53%
Loosely correlated
-0.86%
ARRY - INO
52%
Loosely correlated
-10.22%
ONCO - INO
50%
Loosely correlated
-22.09%
ALNY - INO
42%
Loosely correlated
-8.67%
BTAI - INO
39%
Loosely correlated
+9.20%
More